Somedeb Ball, MBBS
Somedeb Ball, MBBS, is an Assistant Professor in the Division of Hematology and Oncology, Department of Medicine at Vanderbilt Health. He is a clinical and translational investigator specializing in myeloid hematologic malignancies, particularly Myelodysplastic Syndromes (MDS), chronic myelomonocytic leukemia (CMML), and Acute Myeloid Leukemia (AML).
Bhagirathbhai Dholaria, MBBS
Bhagirathbhai Dholaria, MBBS, is an Associate Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine at Vanderbilt Health. His areas of interest are malignant hematology and cellular immunotherapies with a focus on lymphoid and plasma cell malignancies.
Adetola Kassim, MBBS
Adetola Kassim, MBBS, Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine at Vanderbilt Health, treats patient care not merely as a profession, but as a humanitarian and global health mission. He is a clinical researcher in hematology and stem cell transplant and cellular therapy (SCT), focused on advancing the care and treatment outcomes for adults with sickle cell disease (SCD). SCT is a curative modality in the management of various benign and malignant hematologic disorders.
Daniel W. “Trey” Lee, MD
Daniel W. “Trey” Lee, MD, is a pediatric hematologist/oncologist, Associate Professor of Pediatrics and Internal Medicine, and the Director of Pediatric Hematopoietic Stem Cell Transplant and Cell Therapy program at the University of Virginia (UVA).
David Miklos, MD
David Miklos, MD, PhD, is the Chief of Stanford BMT and Cell Therapy Program that provides 750 cancer cell therapies annually. He is a seasoned hematopoietic cell transplant (HCT) clinician and immunologist with special interest in B cell biology, tumor immunology and graft versus host disease (GVHD).
Sattva S Neelapu, MD
Sattva S Neelapu, MD, is Professor and Deputy Chair in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, Houston. As a physician-scientist at MD Anderson, his research is focused on clinical and translational development of novel immunotherapies for lymphoid malignancies.
Ajay Nooka, MD
Ajay K. Nooka, MD, MPH, is the Director of the Myeloma Program in the Department of Hematology & Oncology, Emory University and primarily focuses on multiple myeloma treatment and research. He is the Associate Director for Clinical Research at Winship Cancer Institute, where he oversees clinical research.
Olalekan Oluwole, MD, MPH
Olalekan Oluwole, MD, MPH, is an Associate Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine at Vanderbilt Health. He specializes in the treatment of malignant hematologic disorders with research focus on Chronic Lymphocytic Leukemia (CLL), Hodgkin and non-Hodgkin lymphomas. He is engaged in clinical trials using targeted therapies aimed at improving treatment outcomes in patients with hematologic malignancies.
Ben Ho Park, MD, PhD
Ben Ho Park, MD, PhD, is the Benjamin F. Byrd, Jr. Chair in Oncology, Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Director of the Vanderbilt-Ingram Cancer Center. His research program involves identifying and validating genetic targets for breast cancer therapy and diagnostics.
Karen Proctor, RN, MSN, NE-BC
Serves as Administrative Director of Nursing for the Hematology and Stem Cell Transplant Program at Vanderbilt-Ingram Cancer Center. With extensive experience in oncology and transplant care, she provides strategic and operational leadership for nursing services across the continuum of care. Karen is passionate about advancing excellence in stem cell transplantation through interdisciplinary collaboration, workforce development, quality improvement and innovative care delivery models that enhance patient outcomes. Her work focuses on building high performing teams and supporting the evolving needs of patients undergoing complex cellular therapy and transplant treatments.
Bipin Savani, MD
Bipin Savani, MD, is Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, at Vanderbilt Health. His area of specialization is in the treatment of hematological malignancies, stem cell transplantation/cellular therapy, and his primary field of research is in the long-term follow-up after transplantation/cellular therapy, including regimen-related toxicity/supportive care, and outcomes analysis of hematological malignancies, transplant and cellular therapy recipients.
Salyka Sengsayadeth, MD
Salyka Sengsayadeth, MD, is an Associate Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, at Vanderbilt Health. She has expertise in stem cell transplantation and currently serves as the director of the VA Stem Cell Transplant and Cellular Therapy Program.